- Home
- ANTX vs ICMB Comparison
ANTX vs ICMB Comparison
Compare ANTX & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- ICMB
- Stock Information
- Founded
- ANTX 2017
- ICMB 2012
- Country
- ANTX United States
- ICMB United States
- Employees
- ANTX N/A
- ICMB N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- ICMB Finance: Consumer Services
- Sector
- ANTX Health Care
- ICMB Finance
- Exchange
- ANTX Nasdaq
- ICMB Nasdaq
- Market Cap
- ANTX 40.0M
- ICMB 46.5M
- IPO Year
- ANTX 2022
- ICMB N/A
- Fundamental
- Price
- ANTX $1.44
- ICMB $3.05
- Analyst Decision
- ANTX Hold
- ICMB
- Analyst Count
- ANTX 5
- ICMB 0
- Target Price
- ANTX $3.50
- ICMB N/A
- AVG Volume (30 Days)
- ANTX 298.6K
- ICMB 36.9K
- Earning Date
- ANTX 11-13-2024
- ICMB 02-10-2025
- Dividend Yield
- ANTX N/A
- ICMB 15.63%
- EPS Growth
- ANTX N/A
- ICMB N/A
- EPS
- ANTX N/A
- ICMB 0.29
- Revenue
- ANTX N/A
- ICMB $24,827,371.00
- Revenue This Year
- ANTX N/A
- ICMB N/A
- Revenue Next Year
- ANTX N/A
- ICMB N/A
- P/E Ratio
- ANTX N/A
- ICMB $10.46
- Revenue Growth
- ANTX N/A
- ICMB N/A
- 52 Week Low
- ANTX $0.87
- ICMB $2.91
- 52 Week High
- ANTX $22.22
- ICMB $3.96
- Technical
- Relative Strength Index (RSI)
- ANTX 56.85
- ICMB 39.43
- Support Level
- ANTX $1.23
- ICMB $3.02
- Resistance Level
- ANTX $1.43
- ICMB $3.24
- Average True Range (ATR)
- ANTX 0.09
- ICMB 0.08
- MACD
- ANTX -0.01
- ICMB -0.02
- Stochastic Oscillator
- ANTX 58.33
- ICMB 13.64
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.